Viracta Therapeutics, Inc.
(NASDAQ : SNSS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -4.45%160.070.0%$1484.90m
NVAXNovavax, Inc. -6.32%84.6578.2%$581.13m
AMGNAmgen, Inc. -0.52%227.721.4%$512.75m
BIIBBiogen, Inc. -2.39%220.521.8%$496.77m
GILDGilead Sciences, Inc. 1.03%68.511.0%$492.03m
BNTXBioNTech SE -5.77%147.500.0%$413.51m
REGNRegeneron Pharmaceuticals, Inc. 1.14%621.402.7%$402.73m
ILMNIllumina, Inc. -3.81%365.943.3%$378.85m
VRTXVertex Pharmaceuticals, Inc. -0.23%228.081.9%$340.95m
SNSSSunesis Pharmaceuticals, Inc. -3.99%2.650.7%$185.24m
EXASEXACT Sciences Corp. -2.63%74.0317.9%$168.66m
ARNAArena Pharmaceuticals, Inc. -0.58%90.4813.7%$131.37m
INCYIncyte Corp. 0.04%74.792.4%$130.18m
ALNYAlnylam Pharmaceuticals, Inc. -1.37%136.418.2%$125.00m
BMRNBioMarin Pharmaceutical, Inc. 0.24%84.654.2%$103.18m

Company Profile

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.